SoraTram

{ "short_title": "SoraTram", "data_mode": "900", "data_mode_number": "000002247", "official_title": "Cross-institutional, prospective, open label, single group basket study of combined CRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutations with impaired kinase activity ", "accrual_state": "running", "therapeutic_value": "therapeutic", "therapieansatz_value": "palliativ", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": null, "eudract_number": "2018-003237-16", "general_contact_email": "ctc-trialsite@ukdd.de", "general_contact_phone": "+49 351-4585119", "hauptpruefer_dd_name": "Dr. med. Christoph Heining", "description_laie_de": "Multizentrische prospektive, offene, einarmige Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschr\u00e4nkter Kinase-Aktivit\u00e4t", "description_laie_en": "Cross-institutional, prospective, open label, single group basket study of combined CRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutations with impaired kinase activity", "description_expert_de": "Multizentrische prospektive, offene, einarmige Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschr\u00e4nkter Kinase-Aktivit\u00e4t", "description_expert_en": "Cross-institutional, prospective, open label, single group basket study of combined CRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutations with impaired kinase activity", "rechtsgrundlage_value": "AMG", "phase_amg_value": "I", "main_cat_id": 1, "sub_cat_id": 2 }